Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naive patients with Crohn's Disease with Propensity Score adjustment: Maintenance phase results at week-52 from the prospective VEDOIBD study - Di Giuseppe, R.; Plachta-Danielzik, S.; Bokemeyer, B.; Efken, P.; Mohl, W.; Hoffstadt, M.; Krause, T.; Schweitzer, A.; Schnoy, E.; Atreya, Raja; Teich, N.; Trentmann, L.; et al. (JOURNAL OF CROHNS & COLITIS, 2022)
CRIS-Team WoS Importer:2022-05-13